This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Polyarteritis Nodosa결절성 다발동맥염 (결절성다발동맥염)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: M30.0 | Special Copayment Reduction: V134 (rare disease special copayment reduction)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood: high — the median age of onset is in the 40s~60s, and it is diagnosed far more frequently in adults than in children. Given the nature of systemic vasculitis, diagnosis in childhood is exceptional, and most patients are diagnosed when they first visit a medical institution in adulthood with symptoms such as fever, myalgia, neuropathy, and hypertension.
1. History1866 first description by Kussmaul and Maier → 1903 renamed 'polyarteritis nodosa' → 1990 ACR classification criteria → 1994 and 2012 revised CHCC nomenclature.
2. CausesMedium-vessel vasculitis of unknown cause; HBV-associated (30~40% in the past), ANCA negativity a required criterion. Immune complex-mediated vascular injury is central.
3. GeneticsAssociated with MEFV and HLA-DR7 polymorphisms; polygenic-environmental interaction without a single-gene defect. ANCA negativity is a required diagnostic criterion.
4. General epidemiologyAnnual incidence 0.2~0.9 per 100,000; male predominance in the 40s~60s; HBV-related form decreased after HBV vaccination. Sporadic occurrence worldwide.
5. PathophysiologyImmune complex deposition → complement activation → neutrophil recruitment → transmural fibrinoid necrosis of medium-sized arteries → microaneurysms, thrombosis, ischemic infarction.
6. SymptomsSystemic symptoms such as fever, weight loss, fatigue; mononeuritis multiplex (foot drop); renovascular hypertension; livedo reticularis; abdominal pain (intestinal ischemia); testicular pain.
7. SignsHypertension, asymmetric peripheral nerve deficits, livedo reticularis and subcutaneous nodules, ANCA negative, elevated ESR/CRP. Microaneurysms on angiography.
8. ScreeningNo general population screening. Vasculitis monitoring in HBV-infected individuals; vasculitis panel in patients with mononeuritis multiplex, resistant hypertension, or fever of unknown origin.
9. Diagnosis1990 ACR criteria (3 or more of 10 items) + ANCA negative + HBV testing. Confirmation: tissue (fibrinoid necrotizing vasculitis) or angiography (microaneurysms).
10. TreatmentSteroids + cyclophosphamide (severe, FFS≥2). HBV-related: antiviral agents + short-term steroids + plasma exchange. Remission maintenance: azathioprine, methotrexate.
11. Prognosis5-year survival about 75~80%; cardiac, renal, and intestinal ischemia are the main causes of death. Remission possible with early treatment. FFS ≥ 2 points is a poor prognostic indicator.
12. PreventionHBV vaccine (primary prevention); antiviral treatment of HBV-infected individuals; prevention of relapse after confirmation with remission maintenance agents and regular follow-up.
13. References10 major international journals and guidelines

1. History

The history of polyarteritis nodosa began in 1866 when German physicians Adolf Kussmaul and Rudolf Maier first described a fatal systemic disease in a 22-year-old man accompanied by fever, myalgia, neuropathy, renal failure, and cardiac abnormalities. They found nodular lesions formed repeatedly in the walls of small and medium-sized arteries and named the disease 'periarteritis nodosa'. Later, in 1903, Ferrari of Italy clarified that the affected arteries are involved not only around the artery but across the full thickness of the arterial wall, and proposed renaming it 'polyarteritis nodosa'.

In the early to mid-20th century, understanding of the pathological features of this disease deepened. In 1948, Arkin systematically described the pathological findings across the acute, subacute, and chronic stages. In the 1950s~60s, attention to its similarity to serum sickness brought the immune complex mechanism into focus. In particular, the association between hepatitis B virus (HBV) and polyarteritis nodosa was first proposed by Gocke et al. in the 1970s, and HBV-related polyarteritis nodosa was established as an important subtype accounting for about 30~40% of the total.

An important milestone in vasculitis classification was the establishment of the classification criteria by the American College of Rheumatology (ACR) in 1990. These criteria, based on 10 items, achieved a sensitivity of 82.2% and a specificity of 86.6%, and served as the basis for clinical research for decades afterward. A more fundamental change came when the international conference of vasculitis experts (Chapel Hill Consensus Conference, CHCC) organized vasculitis nomenclature in 1994. The CHCC defined polyarteritis nodosa as a medium-vessel vasculitis and separated diseases involving small vessels, previously collectively called polyarteritis nodosa, into separate disease entities. The CHCC nomenclature revised in 2012 defined polyarteritis nodosa even more clearly as an ANCA-negative medium-vessel vasculitis. In Korea, registration and management as a rare disease began in the early 2000s, and the special copayment reduction code V134 has been assigned, so medical expense reduction benefits apply.


2. Causes

By cause, polyarteritis nodosa is broadly divided into idiopathic and secondary. Idiopathic cases currently account for the majority, and among secondary cases, the hepatitis B virus (HBV)-related form is the most important subtype.

Hepatitis B virus (HBV)-associated polyarteritis nodosa: HBV infection has traditionally been the best-characterized secondary cause. In the 1970s~80s, 30~40% of all polyarteritis nodosa was reported to be HBV-related, but after widespread HBV vaccination this decreased to 7~8% in developed countries. In patients positive for HBV surface antigen (HBsAg), deposition of viral antigen-antibody immune complexes in vessel walls activates complement and recruits neutrophils, causing vascular inflammation and necrosis. HBV-related polyarteritis nodosa usually develops within a few months after HBV infection, and the fact that the vasculitis often improves when the underlying infection is controlled with antiviral treatment supports this association.

Other secondary causes: hepatitis C virus (HCV) is also rarely associated with polyarteritis nodosa, but HCV mainly causes cryoglobulinemic vasculitis. A strong association between hairy cell leukemia and polyarteritis nodosa has been reported, and rare cases occurring after HIV, cytomegalovirus (CMV), and parvovirus B19 infection have also been reported. Drug induction (minocycline, some biologic agents) is also possible.

Pathogenesis of idiopathic polyarteritis nodosa: the exact cause of idiopathic polyarteritis nodosa, which occurs without a clear external antigen, is unknown. The interaction of genetic predisposition (HLA-DR7, MEFV mutations, etc.) and environmental factors is presumed to play an important role. Importantly, ANCA (antineutrophil cytoplasmic antibody) is negative in idiopathic polyarteritis nodosa, which is an important negative defining criterion distinguishing it from microscopic polyangiitis, Churg-Strauss, and Wegener granulomatosis. The fact that polyarteritis nodosa does not cause glomerulonephritis also distinguishes it from other ANCA-associated vasculitides.


3. Genetics

Polyarteritis nodosa is understood not as a monogenic disease caused by a single gene mutation, but as a complex genetic disease arising from the complex interaction of multiple genetic predispositions and environmental factors. Therefore, specific genotype analysis is not essential for diagnosis, but several genetic variants are known to increase susceptibility.

MEFV gene and polyarteritis nodosa: the most notable genetic association is with MEFV gene variants, which cause familial Mediterranean fever (FMF). The MEFV gene is located on the short arm of chromosome 16 (16p13.3) and encodes the pyrin protein. Pyrin is involved in the regulation of the NLRP3 inflammasome, and MEFV variants cause excessive IL-1β secretion and neutrophil hyperactivation. MEFV heterozygous variants are common in Mediterranean populations such as Middle Eastern, Turkish, Armenian, and Jewish peoples, and there are reports that the frequency of polyarteritis nodosa is relatively high in these populations. In particular, there are studies finding MEFV variants in about 30~50% of pediatric polyarteritis nodosa.

HLA association: there are reports that major histocompatibility complex (MHC)-related genes, particularly HLA-DR7, are associated with susceptibility to polyarteritis nodosa. In HBV-related polyarteritis nodosa, associations with HLA-B8 and DR3 have also been reported.

Cytokine gene polymorphisms: there are studies showing that polymorphisms in the promoter regions of the TNF-α, IL-6, and IL-1β genes modulate the intensity of the inflammatory response and are associated with the clinical severity of polyarteritis nodosa and other systemic vasculitides. However, no established genetic risk variants specific to polyarteritis nodosa have yet been identified. A family history is rarely reported in polyarteritis nodosa, the pattern of inheritance does not follow Mendelian inheritance, and most cases are sporadic.


4. General epidemiology

Polyarteritis nodosa is an uncommon, rare autoimmune vasculitis with a reported annual incidence of about 2~9 per million population (0.2~0.9 per 100,000), though there is considerable variation between studies. The prevalence is estimated at 31~33 per million. It occurs in all races worldwide, but incidence may differ by race, and there are also reports that it is relatively higher in the Mediterranean, Middle East, and East Asia.

Sex and age distribution: by sex, men are affected about 2~3 times more often than women, and male predominance is more pronounced in HBV-related polyarteritis nodosa. The age of onset is mainly 40~60 years, with a predilection for middle age and older, but it can also occur in children. Unlike the adult form, pediatric polyarteritis nodosa more commonly involves the skin, and its systemic symptoms may differ somewhat.

Changes in the epidemiology of HBV-associated polyarteritis nodosa: before hepatitis B vaccination became universal (1970s~80s), about 30~40% of patients with polyarteritis nodosa were reported to be associated with HBV infection. Following the spread of the HBV vaccine (introduced in Korea in 1982, with universal neonatal vaccination starting in 1991) and antiviral treatment, HBV-related polyarteritis nodosa decreased markedly to 5~7% of the total in Europe and the United States, and a similar trend is observed in Korea. Accordingly, idiopathic polyarteritis nodosa now accounts for the majority.

Epidemiology in Korea: data on the exact incidence and prevalence in Korea are limited, but according to the Health Insurance Review & Assessment Service (HIRA) and Korean rare disease data, the number of patients registered with an M30.0 diagnosis is estimated at a few hundred. Many patients are managed through special copayment reduction V134 registration, but since the 2012 revision of the CHCC nomenclature, the number of patients classified as 'polyarteritis nodosa' has decreased compared with before, because some patients with small-vessel involvement previously diagnosed with polyarteritis nodosa have been reclassified as microscopic polyangiitis and other diseases.


5. Pathophysiology

The core pathology of polyarteritis nodosa is necrotizing vasculitis involving the full thickness of medium and small muscular arteries. This inflammatory process destroys the structure of the vessel wall, leading to aneurysm formation, thrombus formation, vascular occlusion, and ischemic injury.

Immune complex-mediated mechanism: in HBV-related polyarteritis nodosa, immune complexes composed of viral surface antigen (HBsAg) and antibodies against it (anti-HBs) form in the blood. These immune complexes deposit on the vascular endothelium and activate the complement system. The complement cleavage products C3a and C5a (anaphylatoxins) degranulate mast cells and, as potent chemotactic factors, recruit neutrophils and monocytes to the vascular lesion sites. Activated neutrophils release the oxidative burst, proteases, and neutrophil extracellular traps (NETs), damaging vascular endothelial cells and medial smooth muscle cells.

Acute-phase pathological findings: in the early (acute) phase, inflammatory cell infiltration dominated by polymorphonuclear leukocytes (neutrophils, eosinophils) appears throughout the full thickness of the affected arterial wall, and fibrinoid necrosis of the vascular media is characteristic. At this stage the vascular structure is weakened and focal microaneurysms form, which are the pathological basis of microaneurysms, the key imaging finding of polyarteritis nodosa.

Subacute to chronic pathology: after acute neutrophil infiltration, the process transitions to a chronic inflammatory stage dominated by monocytes and lymphocytes, and intimal hyperplasia develops, narrowing the vascular lumen, which leads to thrombus formation and ischemia of downstream tissues. A characteristic phenomenon of polyarteritis nodosa is the 'coexistence of lesions at various stages', in which acute, subacute, and chronic lesions are mixed within the same artery; observing this phenomenon in histopathological findings favors the diagnosis.

Vascular distribution and ischemic consequences: polyarteritis nodosa selectively involves the medium and small muscular arteries supplying the kidneys, liver, mesentery, heart, muscles, skin, and nerves. The fact that the pulmonary vessels and glomerular capillaries are typically not involved is a major pathological difference from ANCA-associated vasculitis. Renal artery involvement causes renal infarction, aneurysm rupture, and renovascular hypertension; mesenteric artery involvement causes intestinal ischemia and infarction; coronary artery involvement causes myocardial infarction; and involvement of the vessels of peripheral nerves causes mononeuritis multiplex.


6. Symptoms

Polyarteritis nodosa is a systemic vasculitis involving various organs, and because its symptoms are nonspecific and diverse, there is often considerable delay before diagnosis. Clinical symptoms can be divided into systemic symptoms and organ-specific symptoms.

Constitutional symptoms: most patients develop fever, weight loss, generalized fatigue, night sweats, and myalgia over weeks to months. Weight loss often occurs at a significant level (5~10% or more of body weight), and myalgia is often particularly prominent in the lower extremities.

Neurological symptoms: peripheral nerve involvement is a very characteristic and common symptom of polyarteritis nodosa, occurring in about 50~70% of patients. When the small arteries supplying the nerves (vasa nervorum) are involved, mononeuritis multiplex appears. It presents as sudden foot drop (peroneal nerve involvement), wrist drop (radial nerve involvement), sensory loss, burning pain, paresthesia, and so on.

Renal symptoms: renal involvement occurs in about 40~60% of patients. Renal involvement in polyarteritis nodosa is due to renal arterial vasculitis, not glomerulonephritis, and renovascular hypertension is the most common and important clinical manifestation. In severe cases, renal infarction may occur, presenting with sudden flank pain and hematuria.

Skin symptoms: skin involvement appears in about 30~50% of patients. The most characteristic skin finding is livedo reticularis, a net-like purplish skin discoloration appearing mainly on the lower extremities. Subcutaneous nodules of the lower extremities are often distributed along the course of arteries, and ischemic ulcers form after necrosis.

Abdominal symptoms: mesenteric artery involvement causes symptoms of intestinal ischemia such as postprandial pain (intestinal angina), diarrhea, nausea, and bloody stools. In severe cases, intestinal infarction may cause acute abdominal pain and a surgical emergency.

Cardiac and testicular symptoms: coronary artery involvement rarely causes myocardial ischemia or infarction and pericarditis, in which case the prognosis is poor. In men, testicular pain and tenderness may occur, due to involvement of the testicular artery. When polyarteritis nodosa is suspected, testicular pain is an important diagnostic clue.


7. Signs

In polyarteritis nodosa, physical signs vary depending on the organs involved and the stage of disease progression.

Vital signs: fever (body temperature 38℃ or higher) is commonly observed as an indicator of active inflammation. Hypertension is an important sign of polyarteritis nodosa; it is often due to renovascular hypertension and may present as resistant hypertension with a systolic blood pressure of 160 mmHg or higher.

Neurological signs: asymmetric peripheral nerve deficits due to mononeuritis multiplex are characteristic. Foot drop is due to peroneal nerve involvement, making ankle dorsiflexion impossible. With radial nerve involvement, wrist drop is observed, and with ulnar nerve involvement, weakness of finger abduction. Deep tendon reflexes are decreased or absent in the affected nerves.

Skin signs: livedo reticularis is a net-like purplish skin discoloration observed on the medial aspect of the lower extremities, which worsens with cold exposure. Subcutaneous nodules are located along the course of arteries and are palpated as tender nodules 0.5~2 cm in size.

Laboratory findings: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are markedly elevated. On urinalysis, there may be only proteinuria without hematuria or red cell casts, but marked hematuria and red cell casts suggest microscopic polyangiitis rather than polyarteritis nodosa. ANCA (MPO, PR3) must be negative, and HBV association is checked with HBsAg, anti-HBc, and HBV DNA tests.

Imaging signs: on CTA or angiography of the abdominal and renal arteries, microaneurysms with alternating stenosis and dilatation are characteristic. Finding these features in the renal, hepatic, and mesenteric arteries provides strong evidence for the diagnosis of polyarteritis nodosa.


8. Screening

There is no systematic screening program for polyarteritis nodosa targeting the general population. This is because its prevalence is low and its nonspecific prodromal symptoms overlap with various diseases, making a cost-effective population-wide screening strategy impossible.

Monitoring of HBV-infected individuals: in HBsAg-positive patients with chronic hepatitis B, vasculitis evaluation should be performed when symptoms suggestive of systemic vasculitis such as fever, myalgia, weight loss, or neuropathy appear. Because HBV-related polyarteritis nodosa tends to develop within a few months after HBV infection, particular attention is required in newly HBV-infected individuals.

Symptom-based targeted screening: evaluation for systemic vasculitis, including polyarteritis nodosa, should be performed in patients presenting with the following clinical combinations. First, when mononeuritis multiplex of unknown cause develops; second, when resistant hypertension develops suddenly in a young patient; third, when fever of unknown origin (FUO) occurs together with weight loss and malignancy has been excluded; fourth, when symptoms of intestinal ischemia of unknown cause appear.

Initial screening tests: when clinically suspected, the following tests are performed first. Complete blood count (CBC), ESR, CRP; urinalysis (including urine sediment); serum creatinine, liver function; ANCA (MPO-ANCA, PR3-ANCA) — negative in polyarteritis nodosa; HBsAg, anti-HBc, HBV DNA; complement (C3, C4). If ANCA is positive, ANCA-associated vasculitis should be considered first rather than polyarteritis nodosa.

Tissue biopsy screening guide: if vasculitis is strongly suspected based on symptoms and initial tests, vasculitis is confirmed by biopsy of an accessible lesion site (skin nodule, combined sural nerve-gastrocnemius biopsy), and vascular imaging (CTA, MRI/MRA) is performed at the same time.


9. Diagnosis

The diagnosis of polyarteritis nodosa is made by integrating clinical symptoms, blood tests, imaging findings, and histopathological findings, and the definition of the 2012 CHCC nomenclature and the 1990 ACR classification criteria are used as diagnostic aids.

1990 ACR classification criteria: polyarteritis nodosa is classified when 3 or more of the following 10 items are met (sensitivity 82.2%, specificity 86.6%). ①Weight loss ≥ 4 kg, ②livedo reticularis, ③testicular pain or tenderness, ④myalgia, weakness, or leg tenderness, ⑤mononeuritis multiplex or polyneuropathy, ⑥diastolic blood pressure > 90 mmHg (new onset), ⑦BUN > 40 mg/dL or creatinine > 1.5 mg/dL, ⑧HBsAg or HBs antibody seropositivity, ⑨aneurysm or occlusion on arteriography, ⑩arterial wall infiltration including polymorphonuclear leukocytes on biopsy of a small or medium-sized artery.

Blood and urine tests: a basic vasculitis panel (ESR, CRP, CBC, urinalysis, renal function, liver function, ANCA, HBV markers) is performed. ANCA negativity is essential for diagnosis.

Tissue examination (biopsy): biopsy of a symptomatic site can provide a definitive diagnosis. Skin nodule biopsy is the most accessible method and can confirm fibrinoid necrotizing vasculitis of subcutaneous vessels. Combined sural nerve-gastrocnemius muscle biopsy is the standard method for confirming vasculitis of the arteries supplying the nerves in patients with mononeuritis multiplex. Renal biopsy is in principle not performed because of the risk of renal aneurysm rupture.

Vascular imaging: when tissue biopsy is not possible or is negative, vascular imaging is an important diagnostic aid. Multiple microaneurysms in the renal, hepatic, and mesenteric arteries with alternating stenoses and occlusions on CT angiography (CTA) are the characteristic imaging findings of polyarteritis nodosa. CTA is currently preferred as the first-line noninvasive imaging method, and high-resolution MR angiography (MRA) can also be used.

Nerve conduction studies: nerve conduction studies (NCS) and electromyography (EMG) are performed to confirm mononeuritis multiplex. An asymmetric axonal injury pattern is the typical finding.


10. Treatment

The goals of treatment of polyarteritis nodosa are to suppress vascular inflammation, prevent organ damage, and maintain remission. The treatment strategy differs greatly depending on whether the disease is HBV-related and on its severity.

Treatment of idiopathic polyarteritis nodosa: when there is severe or life-threatening organ involvement, the combination of high-dose glucocorticoids (steroids) and cyclophosphamide (CYC) is the standard treatment. After intravenous methylprednisolone pulse therapy, oral prednisolone is started at 1 mg/kg/day (maximum 80 mg) and tapered over several months. Cyclophosphamide is given as intravenous pulse therapy (15 mg/kg at 2~3-week intervals) or orally (2 mg/kg/day) for 3~6 months or more, then switched to a remission maintenance agent.

Remission maintenance therapy: after remission is achieved, treatment is switched to azathioprine (2 mg/kg/day) or methotrexate (20~25 mg/week) and maintained for 12~18 months or longer. In case of relapse, reintroduction of cyclophosphamide is considered.

Treatment of HBV-related polyarteritis nodosa: the treatment principles are ① suppression of acute inflammation with short-term steroids, ② suppression of HBV replication with antiviral treatment (entecavir or tenofovir), and ③ removal of immune complexes by plasma exchange when necessary. Steroids are limited to short-term use, and the use of immunosuppressants (cyclophosphamide, etc.) is in principle avoided because of the risk of HBV activation.

Prognostic assessment based on the Five-Factor Score (FFS): proteinuria > 1 g/day, creatinine > 1.58 mg/dL, cardiac involvement, gastrointestinal involvement, and central nervous system involvement each score 1 point, and with FFS ≥ 2 points, combination with cyclophosphamide is strongly recommended.

Supportive treatment: renovascular hypertension requires aggressive antihypertensive treatment including renin-angiotensin system blockers (ACE inhibitors or ARBs). To prevent osteoporosis due to long-term steroid administration, calcium and vitamin D supplementation and prophylactic bisphosphonates are given. When cyclophosphamide is used, adequate fluid intake and mesna administration are given to prevent hemorrhagic cystitis.


11. Prognosis

The prognosis of polyarteritis nodosa was very poor in the pre-treatment era, with 1-year mortality reaching about 80%, but it has improved greatly since the introduction of modern steroid and immunosuppressive treatment. The 5-year survival rate of currently treated patients is about 75~80%, but there are large differences depending on prognostic factors.

Major prognostic factors: the presence of organ involvement included in the Five-Factor Score (FFS) is the most important prognostic factor. Mortality is markedly higher in patients with elevated creatinine (renal failure), proteinuria, cardiac involvement, gastrointestinal involvement (intestinal ischemia or infarction), or central nervous system involvement. The 5-year mortality in patients with FFS ≥ 2 points is reported to be 2~3 times higher than in patients with FFS 0 points.

Causes of death: in patients receiving aggressive treatment, the main causes of death are infection (complication of immunosuppression), cardiovascular complications (myocardial infarction, stroke), renal failure, and surgical complications due to intestinal infarction.

Relapse: the relapse rate of polyarteritis nodosa is lower than that of ANCA-associated vasculitis, reported at about 10~20%. Relapse is rare in HBV-related polyarteritis nodosa once HBV suppression is achieved. In patients who achieve HBeAg seroconversion, the remission rate is high and relapse is rare, and long-term remission is reported to be maintained in about 50~70% of patients.

Long-term complications: in long-term survivors, important causes of long-term morbidity are hypertension, chronic renal failure, sequelae of peripheral neuropathy, osteoporosis, avascular necrosis of the femoral head, cataracts, and diabetes due to long-term steroid administration, and bladder toxicity and increased risk of malignancy (bladder cancer, lymphoma) due to cyclophosphamide.


12. Prevention

Primary prevention of polyarteritis nodosa (preventing its occurrence itself) focuses on preventing HBV infection, a secondary cause, and there is currently no direct primary prevention for idiopathic polyarteritis nodosa.

Primary prevention — HBV vaccination: hepatitis B vaccination is the most effective public health measure for preventing HBV-related polyarteritis nodosa. Korea runs universal neonatal vaccination (since 1991), a 3-dose infant series, and a subsidized vaccination program for unvaccinated adults.

Secondary prevention in HBV-infected individuals: in patients with chronic hepatitis B, suppressing HBV replication with early antiviral treatment (entecavir, tenofovir) can lower the risk of developing HBV-related polyarteritis nodosa. In addition, in HBsAg-positive patients, prophylactic antiviral treatment must be given before starting immunosuppressive treatment to prevent HBV reactivation.

Prevention of relapse (tertiary prevention): to prevent relapse in patients being treated for polyarteritis nodosa, it is important not to taper steroids too quickly and to maintain remission maintenance agents (azathioprine, methotrexate) sufficiently. Regular follow-up (ESR, CRP, urinalysis, neurological evaluation) is needed for early detection of relapse.

Prevention of immunosuppression complications: to minimize complications of long-term steroid treatment, osteoporosis prevention (calcium 1,000~1,500 mg/day, vitamin D 800~1,000 IU/day, bisphosphonates), prevention of opportunistic infection (prophylactic trimethoprim-sulfamethoxazole to prevent Pneumocystis jirovecii pneumonia), avoidance of live vaccines during immunosuppression, and inactivated influenza and pneumococcal vaccination are recommended.

Patient education: patients with polyarteritis nodosa should be educated to recognize symptoms of relapse (fever, myalgia, worsening neuropathy, worsening hypertension, etc.) and to inform their medical team early. They should always carry a medical alert card and consult their attending physician before starting nonsteroidal anti-inflammatory drugs or any new medication.


13. References

  1. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33(8):1088-1093. PMID: 2202309.

  2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. DOI: 10.1002/art.37715.

  3. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17-28. PMID: 8569467.

  4. Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa. Arthritis Rheum. 2010;62(2):616-626. DOI: 10.1002/art.27240.

  5. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa. Medicine (Baltimore). 2005;84(5):313-322. PMID: 16148731.

  6. Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome. Arthritis Rheum. 2004;51(1):92-99. PMID: 14872461.

  7. Hernández-Rodríguez J, Alba MA, Prieto-González S, Cid MC. Diagnosis and classification of polyarteritis nodosa. J Autoimmun. 2014;48-49:84-89. DOI: 10.1016/j.jaut.2014.01.029.

  8. De Virgilio A, Greco A, Magliulo G, et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev. 2016;15(6):564-570. DOI: 10.1016/j.autrev.2016.02.015.

  9. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr. 2004;145(4):517-522. PMID: 15480376.

  10. Pagnoux C, Guillevin L. Peripheral neuropathy in systemic vasculitides. Curr Opin Rheumatol. 2005;17(1):41-48. PMID: 15604897.